Currently, there are no treatments for early/intermediate AMD. Anti-VEGF treatments for late AMD can prevent disease progression, but only after some vision loss has occurred. By pinpointing the moment of transition from early/intermediate to late AMD, the researchers state that machine learning will substantially contribute to the development of new therapeutics that target slowing AMD progression.
Abstract title: Personalized prognosis in early/intermediate age-related macular degeneration based on drusen regression
Presentation start/end time: Sunday, May 7, 2017, 8:30 - 10:15am
Location: Exhibit/Poster Hall
Abstract number: 15 - A0003
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 12,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders.
All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.